Zhong Guo Jing Ji Wang·2025-10-29 03:27Core Viewpoint - Tian Shi Li (600535.SH) reported a decline in third-quarter revenue but an increase in net profit attributable to shareholders, indicating mixed financial performance for the company in 2025 [1][2]. Financial Performance Summary - The company's third-quarter revenue was 2.022 billion yuan, a year-on-year decrease of 3.27% [1][2]. - Net profit attributable to shareholders was 210 million yuan, reflecting a year-on-year increase of 16.56% [1][2]. - Net profit excluding non-recurring gains and losses was 189 million yuan, showing a year-on-year decline of 23.64% [1][2]. - For the first three quarters of 2025, total revenue was 6.311 billion yuan, down 2.35% year-on-year [2]. - Net profit attributable to shareholders for the first three quarters was 984 million yuan, up 16.88% year-on-year [2]. - Net profit excluding non-recurring gains and losses for the first three quarters was 829 million yuan, down 15.59% year-on-year [2]. - The net cash flow from operating activities was 873 million yuan, a decrease of 26.67% year-on-year [2]. Shareholding Structure Changes - Tian Shi Li's controlling shareholder changed from Tian Shi Li Biological Pharmaceutical Industry Group to China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. after a share transfer [3][4]. - Following the transfer, Tian Shi Li Group and its concerted parties held 261,452,489 shares, representing 17.50% of the total share capital [3][4]. - China Resources Sanjiu directly holds 418,306,002 shares, accounting for 28% of the total share capital [3][4]. - The total transfer price for the shares was approximately 6.21 billion yuan [4].